What Graph Therapeutics does

Graph Therapeutics is a Vienna-based techbio company founded in 2024 that develops an AI-powered, lab-in-the-loop platform for drug discovery in inflammation and immunology (I&I). The core technology — branded the Functional Immune Manifold (FIM) — combines ex vivo perturbation of live patient immune cells with multi-omics data (single-cell RNA-seq, high-content imaging, cell-cell interaction metrics) and active-learning machine learning to identify and validate drug targets against immune-mediated diseases. The platform's distinguishing claim is that it captures actual cellular behavioral responses to intervention rather than static genomic snapshots, with a stated goal of front-loading clinical success and reducing the historically high failure rate of I&I drug candidates in clinical trials. Validated performance includes a 3-fold enrichment over random selection for predicting modulators of disease-associated endpoints in a rheumatoid arthritis research program presented at CytoData 2025 and AAI 2026.

The product surface consists of the Lab-in-the-Loop AI Platform, the Functional Disease Manifold (a large-scale functional perturbation atlas), and the Large Functional Immune Perturbation Atlas being co-developed with Parse Biosciences (announced January 2026) to profile hundreds of millions of cells using Parse's GigaLab Evercode single-cell technology. The company builds on the founding team's prior track record at Allcyte (acquired by Exscientia in 2021), where CEO Gregory Vladimer was CSO and CTO Robert Sehlke led computational platform development before both moved to Exscientia in senior translational roles. Co-founder Prof. Berend Snijder is a Faculty Professor at the Botnar Institute of Immune Engineering (BIIE), which signed a strategic collaboration with Graph in October 2025.

Graph's business model is a hybrid of internal drug pipeline development and future platform out-licensing to pharmaceutical and biotech partners. The company is not yet revenue-generating and operates at 1-10 employees. Total capital raised exceeds $10 million, comprising ~$8.1M in equity (a $1.3M seed from Merantix in Aug 2024, a $3.1M pre-seed in Dec 2024 co-led by SquareOne and Merantix, and a $5M round in Jun 2026 joined by Daphni) plus ~€2.2M in non-dilutive Austrian government grants from FFG and AWS. Customer segments are exclusively enterprise B2B — pharma and biotech firms developing I&I therapeutics — supplemented by academic research collaborations (BIIE) and technology partnerships (Parse Biosciences). Pricing is not publicly disclosed, and the GTM motion is described as sales-led for future out-licensing with channel-partner academic collaborations for R&D.

Name

Graph Therapeutics

Legal name

Graph Therapeutics FlexCo

Website

https://graphtx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Graph Therapeutics is a Vienna-based techbio company developing an AI-driven, lab-in-the-loop platform for inflammation and immunology drug discovery, serving pharmaceutical and biotech firms seeking to reduce clinical trial failure rates by validating targets in live patient immune cells.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Immunology therapeutics
• Precision medicine platform
• Drug target identification
• Biotech research platform

Headquarters

HQ city

Klosterneuburg

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Platform Licensing and Partnerships: Graph Therapeutics generates value through strategic partnerships with pharmaceutical and biotech companies, out-licensing its AI-driven platform technology and validated drug targets. The company is advancing internal drug discovery programs across multiple inflammatory and immune-mediated disease indications, with the maturity of the platform positioning the company for strategic out-licensing opportunities and partnerships.
2. Internal Drug Development: The company is building an internal pipeline of therapeutics in inflammation and immunology. As programs advance through preclinical and clinical development, potential revenue streams include milestone payments, royalties on sales, and co-development arrangements with pharmaceutical partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Graph Therapeutics develops and operates an AI-powered Lab-in-the-Loop platform for inflammation and immunology drug discovery. The platform fuses functional perturbation of live patient immune cells with multi-omics data (the Functional Immune Manifold methodology) and applies active learning algorithms to identify, validate, and prioritize clinically tractable drug targets for inflammatory and immune-mediated diseases. Graph monetizes the platform through out-licensing, co-development partnerships with pharmaceutical companies, and academic research collaborations, while also building an internal drug discovery pipeline.

Product overview

Graph Therapeutics (also referred to as GraphTx) operates as a techbio company developing a unified AI-powered platform for inflammation and immunology drug discovery. The core offering consists of the Lab-in-the-Loop AI Platform, which integrates three main components: the Functional Immune Manifold (FIM) for mapping immune dysfunction through patient cell perturbation and multi-omics integration; the Functional Disease Manifold for capturing cellular behavior responses at scale; and active learning algorithms for iterative experimental design. The platform is being expanded through a partnership with Parse Biosciences to build a Large Functional Immune Perturbation Atlas. The company aims to decode complex immune dysfunction at scale and translate findings into differentiated medicines for immune-mediated diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Lab-in-the-Loop AI Platform Graph's next-generation AI platform that combines ex vivo perturbation of live patient immune cells with multi-omics data and active learning to systematically identify, validate, and prioritize drug targets for inflammation and immunology. It is offered to pharmaceutical and biotech partners for out-licensing, co-development, and collaborative research to reduce clinical trial failure rates in I&I drug discovery.
• Functional Immune Manifold (FIM) A platform technology that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases. FIM merges large-scale functional profiling with sparse transcriptomic data to identify context-dependent, biomarker-stratified targets and is the foundational methodology delivered to pharmaceutical and biotech partners through the Lab-in-the-Loop AI Platform.

Quantifiable outcome

• 3-fold enrichment over random selection for predicting new modulators of disease-associated endpoints in rheumatoid arthritis
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Parse BiosciencescoreTechnology or Integration · 20 January 2026Strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration leverages Graph's lab-in-the-loop platform with Parse's GigaLab to profile hundreds of millions of cells from patients with immune diseases under systematic perturbation. Parse's GigaLab uses Evercode technology to generate massive single cell datasets with unprecedented speed and quality, making the immune system's dynamic behavior accessible to AI-first drug discovery.
• Botnar Institute of Immune Engineering (BIIE)coreStrategic or Co-development Partner · 7 October 2025Strategic research collaboration combining Graph's multi-generation AI-driven precision immunology platform with BIIE's cutting-edge primary immune modeling capabilities. The collaboration aims to advance precision medicine development through joint research programs, computational modeling, and identification of novel biology for new medicines against immune system diseases. Both organizations share resources, expertise, data, and infrastructure. Key members have a decade-long history of working together at the intersection of academic research and commercial innovation.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to build predictive models for therapeutics development. Directly comparable as an AI/ML-enabled platform pursuing disease-modifying targets in serious diseases, with overlap in techbio operating model.
• Exscientia: AI-driven precision medicine company using patient-derived biology and ML for small-molecule drug discovery. Directly comparable given Graph founders' prior roles at Exscientia and the shared precision-medicine, patient-derived-data approach.
• Cellarity: Techbio company developing medicines by targeting cellular behavior rather than single molecular targets, using AI and single-cell omics. Closely comparable in its focus on cellular phenotype, single-cell data, and AI to discover targets across disease areas.
• BigHat Biosciences: AI/ML-guided antibody design company using a wet-lab-in-the-loop platform to engineer next-generation biologics. Comparable in combining machine learning with high-throughput wet-lab experimentation in a closed-loop discovery engine for immunology-relevant biologics.
• Recursion Pharmaceuticals: Techbio company combining high-dimensional biological data, automation, and machine learning to discover novel therapeutics at scale. Closely comparable as a high-throughput, AI-first biology platform pursuing internal pipeline plus pharma partnerships.
• BenevolentAI: AI drug discovery company applying knowledge graphs and ML to identify novel targets and drug repurposing opportunities. Comparable as an AI-first discovery platform targeting inflammatory and immunological diseases with pharma partnerships.
• Owkin: AI biotech company using patient-derived data and ML to discover and develop precision therapeutics, with strong presence in immunology and oncology. Comparable in combining real-world patient biology with AI for target discovery and pharma partnerships.
• Generate:Biomedicines: AI-driven biologics design company using generative models to engineer novel protein therapeutics. Comparable as an ML-native platform pursuing de novo biologic design with an internal pipeline plus pharma partnership model.

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein/biology foundation models to pharmaceutical R&D. A broad incumbent in AI-for-drug-discovery with deeper resources and infrastructure that could compete with or partner alongside Graph.

Others

• Botnar Institute of Immune Engineering (BIIE): Academic immune-engineering research institute in Basel with whom Graph has a strategic research collaboration. Included as an adjacent/ecosystem partner rather than direct competitor, given overlapping precision-immunology focus but non-commercial operating model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/graphtx

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Graph Therapeutics